Your account is not claimed yet. You can sign up with ORCID to claim your account.

Oliver Scherf-Clavel

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 14

Top Venues

Pharmaceutics

Toxics

Cancers

Analytical and bioanalytical chemistry

Julius-Maximilians-Universität Würzburg

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Julius-Maximilians-Universität Würzburg Jul 1o 2017

Germany

Juniorprofessor :: Institute for Pharmacy and Food Chemistry

Publications

Simon Rohner, Martina Gramer, Ivo Wiesweg, Oliver Scherf-Clavel, Peter Wohlsein, Martin Schmelz, Ursula Siebert, Franziska Richter, Manuela Gernert
Present in the Aquatic Environment, Unclear Evidence in Top Predators-The Unknown Effects of Anti-Seizure Medication on Eurasian Otters ( Lutra lutra ) from Northern Germany. Toxics 11 (4) (2023)
Simon Rohner, Martina Gramer, Ivo Wiesweg, Oliver Scherf-Clavel, Peter Wohlsein, Martin Schmelz, Ursula Siebert, Franziska Richter, Manuela Gernert
Present in the Aquatic Environment, Unclear Evidence in Top Predators-The Unknown Effects of Anti-Seizure Medication on Eurasian Otters ( Lutra lutra ) from Northern Germany. Toxics 11 (4) (2023)
Simon Rohner, Martina Gramer, Ivo Wiesweg, Oliver Scherf-Clavel, Peter Wohlsein, Martin Schmelz, Ursula Siebert, Franziska Richter, Manuela Gernert
Present in the Aquatic Environment, Unclear Evidence in Top Predators-The Unknown Effects of Anti-Seizure Medication on Eurasian Otters ( Lutra lutra ) from Northern Germany. Toxics 11 (4) (2023)
Simon Rohner, Martina Gramer, Ivo Wiesweg, Oliver Scherf-Clavel, Peter Wohlsein, Martin Schmelz, Ursula Siebert, Franziska Richter, Manuela Gernert
Present in the Aquatic Environment, Unclear Evidence in Top Predators-The Unknown Effects of Anti-Seizure Medication on Eurasian Otters ( Lutra lutra ) from Northern Germany. Toxics 11 (4) (2023)
Nora Isberner, Anja Gesierich, David Balakirouchenane, Bastian Schilling, Fatemeh Aghai-Trommeschlaeger, Sebastian Zimmermann, Max Kurlbaum, Alicja Puszkiel, Benoit Blanchet, Hartwig Klinker, Oliver Scherf-Clavel
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma. Cancers 14 (19) (2022)
Anton Straub, Maximilian Stapf, Markus Fischer, Andreas Vollmer, Christian Linz, Thiên-Trí Lâm, Alexander Kübler, Roman C Brands, Oliver Scherf-Clavel, Stefan Hartmann
Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw. International journal of environmental research and public health 19 (22) (2022)
Bettina Gerner, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, Götz Ulrich Grigoleit, Sebastian Zimmermann, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics 14 (12) (2022)
Bettina Gerner, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, Götz Ulrich Grigoleit, Sebastian Zimmermann, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics 14 (12) (2022)
Bettina Gerner, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, Götz Ulrich Grigoleit, Sebastian Zimmermann, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics 14 (12) (2022)
Bettina Gerner, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, Götz Ulrich Grigoleit, Sebastian Zimmermann, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics 14 (12) (2022)
Bettina Gerner, Oliver Scherf-Clavel
Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment. Pharmaceutics 13 (6) (2021)
Anna M Mc Laughlin, Eduard Schmulenson, Olga Teplytska, Sebastian Zimmermann, Patrick Opitz, Stefanie L Groenland, Alwin D R Huitema, Neeltje Steeghs, Lothar Müller, Stefan Fuxius, Gerald Illerhaus, Markus Joerger, Frank Mayer, Uwe Fuhr, Stefan Holdenrieder, Georg Hempel, Oliver Scherf-Clavel, Ulrich Jaehde, Charlotte Kloft, null For The On-Target Study Consortium
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers 13 (24) (2021)
Fatemeh Aghai, Sebastian Zimmermann, Max Kurlbaum, Pius Jung, Theo Pelzer, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel
Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma. Analytical and bioanalytical chemistry 413 (2) (2020)
Bettina Friedl, Max Kurlbaum, Matthias Kroiss, Martin Fassnacht, Oliver Scherf-Clavel
A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. Analytical and bioanalytical chemistry 411 (17) (2019)

Oliver Scherf-Clavel.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Oliver Scherf-Clavel